Brain & Behavior Research Foundation Applauds FDA Expert Panel Decision to Recommend Approval of New Depression Treatment
NEW YORK, (Feb. 14, 2019) – The Brain & Behavior Research Foundation (BBRF) is pleased that our funding of both early research and ongoing studies on rapid acting antidepressants has helped lead to the development of a new medication for treatment resistant depression.
“The FDA panel’s recommendation of Esketamine as a new medication for treatment resistant depression is welcome news for people and their families who are impacted by depression,” said Dr. Jeffrey Borenstein, President & CEO of BBRF.